Skip to Content
Merck
CN

SML0331

Prasugrel

≥98% (HPLC)

Synonym(s):

5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate, CS 747, CS-747, Effient, Efient, LY640315

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H20FNO3S
CAS Number:
150322-43-3
Molecular Weight:
373.44
NACRES:
NA.77
PubChem Substance ID:
329825336
UNSPSC Code:
12352200
MDL number:
MFCD09954140

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Prasugrel, ≥98% (HPLC)

InChI

1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3

SMILES string

CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C3CC3)c4ccccc4F

InChI key

DTGLZDAWLRGWQN-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: >5 mg/mL (warmed at 60 °C)

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... P2RY12(64805)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Prasugrel is a thienopyridine prodrug and is considered to be more potent than clopidogrel. It shows a faster generation and also reduces thrombotic events. Prasugrel is less dependent on the CYP (cytochrome P450) enzymes for its conversion to active metabolite.
Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors.
Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors. Prasugrel interacts in an irreversible manner with the residues Cys97 and Cys175 of the human P2Y12-receptor.

Features and Benefits

This compound is featured on the P2 Receptors: P2Y G-Protein Family page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000174550
0000174549
0000152498
0000152498
0000150340

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

D Venetsanos et al.
European heart journal. Acute cardiovascular care, 2048872618803760-2048872618803760 (2018-10-24)
Our aim was to study the impact of sex on anticoagulant treatment outcomes during percutaneous coronary intervention in acute myocardial infarction patients. This study was a prespecified analysis of the Bivalirudin versus Heparin in ST-Segment and Non ST-Segment Elevation Myocardial
Jeffrey A Bakal et al.
European heart journal, 36(6), 385-92a-385-92a (2014-07-12)
Several methods provide new insights into understanding clinical trial composite endpoints, using both conventional and novel methods. The TRILOGY ACS trial is used as a contemporary example to prospectively compare these methods side by side. The traditional time-to-first-event, Andersen-Gill recurrent
Antonio Tello-Montoliu et al.
Platelets, 27(8), 777-783 (2016-06-04)
Everolimus-eluting bioabsorbable scaffolds (BVSs) have exhibited similar long-term clinical outcomes compared to its everolimus-eluting metallic counterparts. However, reports from earlier studies have shown a signal for an increased rate of stent thrombosis. The aim of the current investigation is to
Shigeru Saito et al.
Circulation journal : official journal of the Japanese Circulation Society, 78(7), 1684-1692 (2014-04-25)
Prasugrel is an antiplatelet agent that shows more prompt, potent, and consistent platelet inhibition than clopidogrel. The objective of this study was to confirm the efficacy and safety of prasugrel at loading/maintenance doses of 20/3.75 mg. Japanese patients (n=1,363) with
Matti K Itkonen et al.
Clinical pharmacology and therapeutics, 104(3), 495-504 (2017-11-25)
The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we investigated the effects of two widely used P2Y12 inhibitors on montelukast pharmacokinetics. Clopidogrel (300 mg on day
View All Related Papers

Articles

P2 Receptors: P2Y G-Protein Family Overview

Surface receptors for extracellular nucleotides are called P2 receptors. Learn more about P2Y G protein-coupled receptors, GPCRs, and ionotropic P2 receptors (P2X ligand-gated ion channels, LGICs).

P2受体：P2Y G蛋白家族概述

胞外核苷酸表面受体又称P2受体。了解更多有关 P2Y G 蛋白偶联受体、GPCR 和离子型 P2 受体（P2X 配体门控离子通道，LGIC）的信息。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service